Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06643884
PHASE2

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Sponsor: Aura Biosciences

View on ClinicalTrials.gov

Summary

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.

Official title: A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2024-12-16

Completion Date

2027-10-31

Last Updated

2026-03-13

Healthy Volunteers

No

Interventions

DRUG

AU-011

AU-011 Via Suprachoroidal Administration with laser treatment

DEVICE

SCS Microinjector

Suprachoroidal Injection Device

DEVICE

Laser

Laser Administration

Locations (10)

Byers Eye Institute at Stanford University

Palo Alto, California, United States

Bascom Palmer Eye Institute

Miami, Florida, United States

Massachusetts Eye and Ear

Boston, Massachusetts, United States

Kellogg Eye Center

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Cleveland Clinic, Cole Eye Institute

Cleveland, Ohio, United States

Shields and Shields, PC

Philadelphia, Pennsylvania, United States

Tennessee Retina, PC

Nashville, Tennessee, United States

Retina Consultants of Texas

Bellaire, Texas, United States

University of Washington

Seattle, Washington, United States